Jada Koren Pinkett Smith is an American actress, screenwriter, producer, talk show host, businesswoman, and an occasional singer-songwriter.
The Takeda Pharmaceutical Company Limited[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical and biopharmaceutical company. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US $19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process – from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials – to approved vaccine or drug typically takes more than a decade.
Salvia divinorum is a plant species with transient psychoactive properties when its leaves are consumed by chewing, smoking, or as a tea. The leaves contain opioid-like compounds that induce hallucinations. Because the plant has not been well-studied in high-quality clinical research, little is known about its toxicology, adverse effects, or safety over long-term consumption. Its native habitat is cloud forest in the isolated Sierra Mazateca of Oaxaca, Mexico, where it grows in shady, moist locations. The plant grows to over a meter high, has hollow square stems like others in the mint family Lamiaceae, large leaves, and occasional white flowers with violet calyxes. Botanists have not determined whether Salvia divinorum is a cultigen or a hybrid because native plants reproduce vegetatively and rarely produce viable seed.
Hovione is a Portuguese company that produces active pharmaceutical ingredients (APIs) and conducts drug product intermediates development and compliant manufacture. Hovione is a Contract Development and Manufacturing Company (CDMO) dedicated to helping pharmaceutical customers bring new and off-patent drugs to market. With sites in the United States, Portugal, Ireland and China. The company provides a number of products and services to the pharmaceutical industry including separate or integrated API, pre-formulated compounds, particle engineering, formulation development and manufacturing. It also supports highly potent compounds and proprietary product development and licensing for drug products. It is also present in the inhalation area.
Retigabine (INN) or ezogabine (USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011. Production has been discontinued in June 2017.
Elinogrel (INN, USAN) was an experimental antiplatelet drug acting as a P2Y12 inhibitor. Similarly to ticagrelor and in contrast to clopidogrel, elinogrel was a reversible inhibitor that acted fast and short (for about 12 hours), and it was not a prodrug but pharmacologically active itself. The substance was used in form of its potassium salt, intravenously for acute treatment and orally for long-term treatment. Development was terminated in 2012.
Prinaberel is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor. It is used in scientific research to elucidate the role of the ERβ receptor. Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis. Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions.
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
